{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:30:48Z","timestamp":1791862248532,"version":"4.3.4"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamainternmed.2020.2250","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T11:40:01Z","timestamp":1592221201000},"page":"1108","source":"Crossref","is-referenced-by-count":87,"title":["Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration"],"prefix":"10.1001","volume":"180","author":[{"given":"Talal","family":"Hilal","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, University of Mississippi Medical Center, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gonzalez-Velez","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Division of Hematology Oncology, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"},{"name":"Center for Health Care Ethics, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"ioi200036r1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate.","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"12","key":"ioi200036r2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ioi200036r3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration.","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"ioi200036r4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.6004\/jnccn.2013.0077","article-title":"Double-crossed: why crossover in clinical trials may be distorting medical science.","volume":"11","author":"Prasad","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"ioi200036r5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/annonc\/mdy116","article-title":"When is crossover desirable in cancer drug trials and when is it problematic?","volume":"29","author":"Haslam","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"ioi200036r6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.mayocp.2015.05.006","article-title":"Hard-wired bias: how even double-blind, randomized controlled trials can be skewed from the start.","volume":"90","author":"Prasad","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"10183","key":"ioi200036r7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"ioi200036r10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma.","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"7","key":"ioi200036r11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non\u2013small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"ioi200036r12","article-title":"ANNOUNCE: a randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox)?+?olaratumab versus dox?+?PBO in patients (pts) with advanced soft tissue sarcomas (STS)","volume":"37","author":"Tap","year":"2019","journal-title":"J Clin Oncol"},{"issue":"28","key":"ioi200036r13","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1200\/JCO.2005.06.679","article-title":"Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.","volume":"23","author":"Zia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"ioi200036r14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.6004\/jnccn.2019.7345","article-title":"Response rates and durations of response for biomarker-based cancer drugs in nonrandomized versus randomized trials.","volume":"18","author":"Gyawali","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"ioi200036r15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","article-title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.","volume":"28","author":"Vivot","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"ioi200036r16","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jamaoncol.2018.4300","article-title":"Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration based on single-arm trials.","volume":"4","author":"Tibau","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"ioi200036r17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval.","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"ioi200036r18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/jnci\/djy130","article-title":"Overview of oncology and hematology drug approvals at US Food and Drug Administration between 2008 and 2016.","volume":"111","author":"Zhou","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"July","key":"ioi200036r19","article-title":"Surrogate end points and patient-reported outcomes for novel oncology drugs approved between 2011 and 2017.","author":"Zettler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"ioi200036r20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejca.2011.10.028","article-title":"Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?","volume":"48","author":"Amir","year":"2012","journal-title":"Eur J Cancer"},{"issue":"4","key":"ioi200036r21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0003-4975(10)66846-4","article-title":"Effect of crossover on the statistical power of randomized studies.","volume":"48","author":"Weinstein","year":"1989","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"ioi200036r24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/annonc\/mdx793","article-title":"Crossover is not associated with faster trial accrual.","volume":"29","author":"Chen","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"ioi200036r25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/pst.v12.6","article-title":"Adjusting overall survival for treatment switches: commonly used methods and practical application.","volume":"12","author":"Watkins","year":"2013","journal-title":"Pharm Stat"},{"key":"ioi200036r26","doi-asserted-by":"publisher","first-page":"l5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.","volume":"366","author":"Naci","year":"2019","journal-title":"BMJ"},{"issue":"17","key":"ioi200036r27","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"ioi200036r28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer.","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"ioi200036r8","unstructured":"US Food and Drug Administration. Hematology\/oncology (cancer) approvals and safety notifications. Accessed March 11, 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/hematologyoncology-cancer-approvals-safety-notifications"},{"key":"ioi200036r9","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed March 11, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"ioi200036r22","unstructured":"US Food and Drug Administration. Remarks to the National Comprehensive Cancer Network Policy Summit\u201406\/25\/2018. Accessed April 7, 2020. https:\/\/www.fda.gov\/news-events\/speeches-fda-officials\/remarks-national-comprehensive-cancer-network-policy-summit-06252018"},{"key":"ioi200036r23","unstructured":"Kuznar? W. A dynamic FDA has led to more rapid cancer drug development. Accessed April 7, 2020. http:\/\/oncpracticemanagement.com\/issues\/2018\/february-2018-vol-8-no-2\/1067-a-dynamic-fda-has-led-to-more-rapid-cancer-drug-development"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2767107\/jamainternal_hilal_2020_oi_200036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T11:06:35Z","timestamp":1596452795000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2767107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2020.2250","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}